Toxoplasmosis treatment drugs market| Coherent Market Insights

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS • Toxoplasmosis Treatment Drugs Market, by Indication (Chronic Toxoplasmosis Infection, and Acute Toxoplasmosis Infection), by Route of Administration ( Parental Route and Oral Route), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Clindamycin, Zithromax, Mepron, Clarithromycin, and Others), by Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

3. Global Toxoplasmosis Treatment Drugs Market: Drivers • The global toxoplasmosis treatment drugs market is expected to witness significant growth during the forecast period as pharmaceutical companies are focusing on research and development of treatments for toxoplasmosis. For instance, in 2018, Vyera Pharmaceuticals LLC received the U.S. Food Drug and Administration (FDA) clearance to initiate Phase 1 study of the VYR-006, which is a potent dihydrofolatereductase (DHFR) inhibitor used for treatment of toxoplasmosis. • Moreover, the growing prevalence of HIV across the globe is increasing risk of toxoplasma gonad infection due to less immune response in HIV infected patients. For instance, according to the World Health Organization (WHO), by the end of 2018, around 37.9 million people across the globe had HIV, therefore it is expected to increase prevalence of toxoplasmosis infection among the global population.

4. Global Toxoplasmosis Treatment Drugs: COVID-19 Impact Analysis • The COVID-19 pandemic has impacted growth of several markets across the globe and it is also expected to hamper the growth of the global toxoplasmosis treatment drugs market during the forecast period. Moreover, safety precautions suggested by the World Health Organization to reduce the spread of COVID-19 and implementation of nationwide lockdowns have affected the supply chain of toxoplasmosis treatment drugs due to higher shipping prices because of reduced excipient supply containers

5. Global Toxoplasmosis Treatment Drugs Market: Restraints • The use of pyrimethanine and sulfadiazine drugs are characterized by side effects in pregnant women such as injury to the fetus and bone marrow suppression. Moreover, according to U.S. Food Drug and Administration’s February 2020 report, the most common side effect of pyrimethamine is hypersensitivity, which leads to severe diseases such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Furthermore, low dosage of promethazine can also cause hematologic effects in patients. These factors are expected to restrain growth of the global toxoplasmosis treatment drugs market.

6. Global Toxoplasmosis Treatment Drugs Market: Regional Analysis • On the basis of region, the global toxoplasmosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2020, North America is expected to account the largest market share in the global toxoplasmosis treatment drugs market owing to factors such as the increasing prevalence of toxoplasmosis infection. According to the Centers for Disease Control and Prevention’s September 2018 report, in the U.S, around 11% of the population in the age group of 6 or older suffered from toxoplasma. • Furthermore, pharmaceutical companies are focusing on research and development of effective treatments for toxoplasmosis to strengthen their market share in the global toxoplasmosis treatment drugs market.  For instance, in February 2020, Cerovene Inc. obtained approval for generic Daraprim (pyrimethamine) tablet for treatment of toxoplasmosis from the U.S. FDA. The drug is used with combination of sulfonamide for treatment of toxoplasmosis bacterial infection. • Europe is expected to witness significant growth in the global toxoplasmosis treatment drugs market due to the rising prevalence of HIV in Europe. For instance, according to the World Health Organization’s 2018 report, over 2 million people in Europe were affected by HIV.

7. Global Toxoplasmosis Treatment Drugs Market: Key Players • Key players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, TajAccura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc. • Market Taxonomy: • On the basis of indication, the global toxoplasmosis treatment drugs market is segmented into: • Chronic Toxoplasmosis Infection • Acute Toxoplasmosis Infection

8. On the basis of route of administration, the global toxoplasmosis treatment drugs market is segmented into: • Parental Route • Oral Route • On the basis of drug class, the global toxoplasmosis treatment drugs market is segmented into: • Pyrimethamine • Spiramycin • Leucovorin • Sulfadiazine • Clindamycin • Zithromax • Mepron • Clarithromycin • Others

9. On the basis of distribution channel, the global toxoplasmosis treatment drugs market is segmented into: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • On the basis of region, the global toxoplasmosis treatment drugs market is segmented into: • North America • Latin America • Europe • Middle East • Asia Pacific • Africa

10. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference: https://www.coherentmarketinsights.com/ongoing-insight/toxoplasmosis-treatment-drugs-market-4166

11. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

12. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

13. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/